Brilinta vs Pradaxa
Side-by-side cost comparison based on Medicare Part D data
Brilinta
Ticagrelor
Manufactured by AstraZeneca
Pradaxa
Dabigatran
Manufactured by Boehringer Ingelheim
Pradaxa costs 21% less per claim than Brilinta ($180.00 vs $229.00). A generic version of Pradaxa is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Brilinta | Pradaxa |
|---|---|---|
| Avg Cost Per Claim | $229.00 | $180.00 |
| Total Medicare Spending | $567.0M | $876.0M |
| Total Beneficiaries | 298,000 | 580,000 |
| Total Claims | 2,480,000 | 4,860,000 |
| Annual Cost/Patient | $1,903.00 | $1,510.00 |
| Year-over-Year Change | -8.4% | -9.8% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | AstraZeneca | Boehringer Ingelheim |
| Condition | Blood Clots | Blood Clots |
| Generic Name | Ticagrelor | Dabigatran |
Brilinta vs Pradaxa: What the Data Shows
Brilinta (Ticagrelor) and Pradaxa (Dabigatran) are both used to treat blood clots. Based on Medicare Part D data, Pradaxa costs $180.00 per claim, which is 21% less than Brilinta at $229.00 per claim.
Medicare spent $567.0M on Brilinta and $876.0M on Pradaxa. In terms of patient reach, Pradaxa serves more beneficiaries (580,000 vs 298,000).
Year-over-year spending changed -8.4% for Brilinta and -9.8% for Pradaxa.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Pradaxa is cheaper at $180.00 per claim, compared to $229.00 for Brilinta. That makes Pradaxa about 21% less expensive per claim based on Medicare Part D data.
Yes, both Brilinta and Pradaxa are used to treat blood clots. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Ticagrelor and generic Dabigatran can offer significant cost savings — typically 80-95% less than the brand name.
Medicare Part D spent $567.0M on Brilinta covering 298,000 beneficiaries, and $876.0M on Pradaxa covering 580,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.